Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Olema Pharmaceuticals ( (OLMA) ) is now available.
Olema Oncology, the operating name of Olema Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other endocrine-driven cancers, with its lead drug palazestrant in two Phase 3 trials and a KAT6 inhibitor, OP-3136, in Phase 1 development. The company operates from San Francisco and Cambridge, Mass., and applies deep expertise in nuclear receptors and resistance mechanisms to build a pipeline intended to raise the standard of care in oncology.
On April 27, 2026, Olema’s board appointed biopharmaceutical veteran Prakash Raman, Ph.D., as an independent Class II director, effective April 28, 2026, with his term running to the 2028 annual meeting of stockholders. Raman, currently CEO of InduPro Therapeutics and former Novartis business development leader, received equity awards under Olema’s director compensation plan, and is expected to bolster the company’s strategic capabilities as it advances palazestrant and OP-3136 and prepares for pivotal data and its next phase of growth.
On April 29, 2026, Olema formally announced Raman’s appointment, highlighting his extensive dealmaking and portfolio strategy experience, including prior roles at Ribon Therapeutics, Flagship Pioneering, and Novartis Institutes for Biomedical Research. Management and the board framed his addition as a key step in supporting Olema’s evolution into a fully integrated oncology company, signaling further maturation of governance and strategic oversight as late-stage programs move toward potential commercialization.
The most recent analyst rating on (OLMA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Olema Pharmaceuticals stock, see the OLMA Stock Forecast page.
Spark’s Take on OLMA Stock
According to Spark, TipRanks’ AI Analyst, OLMA is a Neutral.
The score is held down primarily by weak financial performance driven by no revenue, widening losses, and rising cash burn, alongside bearish technical momentum. A low-debt balance sheet and a positive strategic update support the outlook, but do not offset the near-term funding and execution risks.
To see Spark’s full report on OLMA stock, click here.
More about Olema Pharmaceuticals
Olema Oncology, the operating name of Olema Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for breast cancer and other endocrine-driven cancers. Its lead candidate, palazestrant (OP-1250), an oral complete estrogen receptor antagonist and selective estrogen receptor degrader, is in two Phase 3 trials, while OP-3136, a KAT6 inhibitor, is in Phase 1 development, with operations based in San Francisco and Cambridge, Mass.
The company leverages expertise in nuclear receptors and mechanisms of acquired resistance to advance a pipeline of novel oncology treatments that aim to improve outcomes and transform standards of care for patients globally.
Average Trading Volume: 1,578,080
Technical Sentiment Signal: Buy
Current Market Cap: $1.33B
For detailed information about OLMA stock, go to TipRanks’ Stock Analysis page.